Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Leukemia Hijacks Nucleotide Metabolism
Disease Discoveries

Leukemia Hijacks Nucleotide Metabolism

By Will DossFeb 15, 2021
Share
Facebook Twitter Email
Daniel Foltz, PhD, associate professor of Biochemistry and Molecular Genetics, was senior author of the study published in Science Advances.

T-cell acute lymphoblastic leukemia (T-ALL) uses the NOTCH1 signaling pathway to produce nucleotides, a basic building block of life that fuels growth and spread of the cancer, according to a study published in Science Advances.

This process is downstream of aberrant NOTCH1 signaling, an oncogenic pathway important for many cancers. While NOTCH-specific therapies have fallen flat, the findings open the door to a combination therapy, according to Daniel Foltz, PhD, associate professor of Biochemistry and Molecular Genetics and senior author of the study.

“This aberrant NOTCH signaling feeds into the process of metabolism in the cell,” Foltz said. “We could potentially try combination therapy, which would be particularly relevant in treatment-resistant leukemias.”

The NOTCH pathway is a cell signaling system present in most animals, promoting cell proliferation especially during early development. Mutations in NOTCH1 or aberrant NOTCH1 signaling have been implicated in a variety of cancers, but exactly how these mutated signals promote cancer growth downstream have remained unclear, according to Foltz.

“NOTCH is a transcription factor that binds many genes, but the critical changes required for supporting leukemia formation are not well understood,” Foltz said.

Knowledge of NOTCH1’s downstream targets are still evolving, but one protein — UBR7 — stood out for its role in protein degradation, according to the authors.

Tumor signals in mice from leukemia cells with (left) or without (right) UBR7.

Foltz, along with Shashank Srivastava, PhD, postdoctoral fellow in the Foltz laboratory and lead author of the study, conducted an unbiased screen of protein partners of UBR7. They found that UBR7 interacts with a group of phosphoribosyl pyrophosphate synthetases (PRPSs), essential enzymes for nucleotide synthesis.

Cancer cells, compared to normal cells, have increased energy requirements and must find alternative pathways to feed growth, generating basic molecules such as nucleotides through mutated or aberrant processes.

“These are the actual building blocks that make up DNA and RNA, and are eventually converted into proteins that form the majority of the biomass of cancer cells,” Srivastava said.

The investigators created T-ALL cancer cell lines with and without UBR7, finding that nucleotide production was severely reduced in cell lines deficient in UBR7.

“Nucleotide synthesis is such a fundamental biologic process that is central for cancer proliferation and survival,” Srivastava said.

Shashank Srivastava, PhD, postdoctoral fellow in the Foltz laboratory, was lead author of the study published in Science Advances.

While several cancer therapies targeting the NOTCH1 pathway have been developed and tested, many have exhibited poor efficacy and treatment resistance, Foltz said. Instead, combining NOTCH1 therapies with a downstream UBR7 inhibitor could prove to be a more effective treatment option.

“The cancer uses everything available to evade the immune system and grow without normal regulation,” Foltz said. “Here, we might have an opportunity to regulate the cancer metabolism through UBR7.”

Co-authors of the study include Jeffrey Savas, PhD, assistant professor in the Ken and Ruth Davee Department of Neurology Division of Behavioral Neurology; Panagiotis Ntziachristos, PhD, assistant Professor of Biochemistry and Molecular Genetics and assistant professor of Medicine in the Division of Hematology and Oncology; and Issam Ben-Sahra, PhD, assistant professor of Biochemistry and Molecular Genetics.

Ntziachristos, Ben-Sahra and Foltz are members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

This study was supported by a Zell Scholarship from the Lurie Cancer Center, National Institutes of Health National Institute of Child Health and Human Development grant 1R21HD078946 and National Cancer Institute grant CA248770.

Biochemistry and Molecular Genetics Cancer Genetics Research
Share. Facebook Twitter Email

Related Posts

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

Comments are closed.

Latest News

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642
20230317_NM643
20230317_NM624
20230317_NM303
20230317_NM551
20230317_NM559
20230317_NM536
20230317_NM508

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.